Renaming “Chemobrain”

@article{Hurria2007Renaming,
  title={Renaming “Chemobrain”},
  author={A. Hurria and G. Somlo and T. Ahles},
  journal={Cancer Investigation},
  year={2007},
  volume={25},
  pages={373 - 377}
}
  • A. Hurria, G. Somlo, T. Ahles
  • Published 2007
  • Medicine
  • Cancer Investigation
  • A subset of breast cancer survivors are reporting cognitive impairment after cancer treatment, which has commonly been attributed to the receipt of chemotherapy and colloquially termed “chemobrain.” For some, a fear of this side effect enters into their decision regarding therapy. Our review of the literature reveals that so-called “chemobrain” is complex and that factors other than chemotherapy may affect cognitive function, including the impact of surgery and anesthesia, hormonal therapy… CONTINUE READING
    70 Citations
    Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response
    • 325
    • PDF
    A Meta-Analysis of Cognitive Impairment Following Adult Cancer Chemotherapy
    • 58
    • PDF
    Why, After Chemotherapy, is it Necessary to Assess Memory Using Translational Testing?
    • S. Acevedo
    • Medicine
    • Breast cancer : basic and clinical research
    • 2012
    • 7
    • PDF
    Growth of Malignant Non-CNS Tumors Alters Brain Metabolome
    • 1
    • PDF

    References

    SHOWING 1-10 OF 18 REFERENCES
    Neurocognitive Performance in Breast Cancer Survivors Exposed to Adjuvant Chemotherapy and Tamoxifen
    • 348
    • PDF
    Cognitive dysfunction and chemotherapy: neuropsychological findings in perspective.
    • 49
    Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy
    • 337
    Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma.
    • 655
    The effects of oestrogens and anti-oestrogens on cognition.
    • 38
    Cognitive function in breast cancer patients receiving adjuvant chemotherapy.
    • 508